Merck Serono Strengthens Executive Management Team With Two Appointments

By Merck Serono S A, PRNE
Wednesday, July 6, 2011

GENEVA, July 7, 2011 -

  • Belén Garijo joins as Chief Operating
  • Annalisa Jenkins joins as Global Head of Drug
    Development & Medical
    , following a new organizational
    structure in R&D

Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
announced today that it is strengthening its executive management
team with two appointments. Dr. Belén Garijo has been appointed
Chief Operating Officer, effective September 1, 2011. Dr. Annalisa
has been appointed Global Head of Drug Development &
Medical, effective September 5, 2011. In their newly created
positions, both Belén Garijo and Annalisa Jenkins will be based in
Geneva and report directly to Dr. Stefan Oschmann, President of
Merck Serono.

Belén Garijo joins Merck Serono from Sanofi, where she was
Senior Vice President, Global Operations Region Europe. Annalisa
joins from Bristol-Myers Squibb, where she was Senior Vice
President, Global Medical.

“I am very pleased to have Belén and Annalisa onboard at this
important time for Merck Serono as we seek to adapt our
organization to the challenges the pharmaceutical industry are
facing,” said Stefan Oschmann. “In joining our Executive Management
Board, Belén and Annalisa will bring extensive international
experience in the pharmaceutical industry to lead and drive our
organization through changes aimed to ensure sustained

As Chief Operating Officer, Belén Garijo will have
responsibility for worldwide commercial operations and marketing.
The primary purpose of her role is to define a highly competitive
commercial and marketing strategy to strengthen Merck Serono’s
product brands and lead its global business to profitable growth
across all therapeutic areas. One of her top priorities at Merck
Serono will be to define the future Commercial & Marketing
organizational structure and efficient processes to drive the
successful implementation of the business strategy.

A new organizational structure for research and development
(R&D) will be effective when Annalisa Jenkins joins Merck
Serono. Two dedicated groups, focusing on different stages of
pharmaceutical innovation (pre- and post- proof of concept), will
be created as a first step in redesigning Merck Serono’s R&D

  • The Global Research & Early Development Group, headed by
    Dr. Bernhard Kirschbaum, will include discovery, research and early
    clinical development, through to proof of concept;
  • The Global Drug Development & Medical Group, headed by
    Annalisa Jenkins, will focus on full clinical development, medical
    life-cycle management activities and medical, including regulatory
    and safety functions.

A key priority for Bernhard Kirschbaum and Annalisa Jenkins will
be defining the structures and processes of the new R&D
organization, with the goal of simplifying the organizational
structure, governance and decision-making processes. The new
organizational structure for R&D is expected to foster agility,
creativity and entrepreneurship and to allow a more efficient use
of resources, with the ultimate goal of delivering innovative
medicines that address the unmet needs of patients.

Biography of Dr. Belén Garijo

Belén Garijo is a medical doctor who specialized in clinical

Prior to her appointment at Merck Serono, she was Senior Vice
President, Global Operations Region Europe at Sanofi from 2006 and
served as the Global Integration Leader for the Genzyme

Belén Garijo has served in a range of global executive positions
in healthcare for 20 years, including emerging markets and mature
markets, core prescription medicines as well as diversified,
adjacent businesses (such as generics, medical devices, health
solutions and consumer health care). She has managed large
pharmaceutical operations and medical and marketing organizations
on local, regional and global levels, successfully leading a number
of business transformation projects.

Belén Garijo started her career at Abbott Laboratories as
Medical Director of its Spanish affiliate before heading Global
Medical Affairs at Abbott headquarters in Illinois (USA). She
joined Rhone Poulenc Rorer in 1996 as Business Unit Director of
Oncology in Spain and was promoted in 2000 to be Aventis’ Global
Vice-President Oncology based in New Jersey (USA). She then became
General Manager of Aventis Spain in 2003, leading the integration
towards Sanofi-Aventis in 2004 and serving as General Manager of
Sanofi-Aventis Spain.

Belén Garijo is a Spanish citizen.

Biography of Dr. Annalisa Jenkins

Annalisa Jenkins is a medical doctor who specialized in

Prior to her appointment at Merck Serono, she was Senior Vice
President, Global Medical, at Bristol-Myers Squibb (BMS).

Annalisa Jenkins started her career as a medical officer at the
British Royal Navy and worked subsequently for three years for the
UK National Health Service.

In 1997, she joined BMS and began her career in pharmaceutical
research and development where she rapidly advanced in both
responsibility and expertise. She started as Cardiovascular Medical
Advisor based in the UK. In 2000, she moved to Australia to serve
as Executive Medical Director for Australia and New Zealand, where
she was responsible for executing clinical trials and medical
activities. Within a year of assuming that position, she took on
far broader duties when the company asked her to lead its Medical
Division across Asia Pacific and Latin America.

After completing her overseas assignment, Annalisa Jenkins moved
to BMS’s major R&D site in Princeton, New Jersey to oversee the
company’s worldwide Medical Division composed of 46 medical
departments responsible for medical publications, medical
information and collaborative science.

After three years in this role, she was appointed Chief Medical
Officer for Europe, Middle East and Africa; later she was promoted
to Senior Vice President and Chief Medical Officer responsible for
the Americas and the Development Teams. Prior to assuming her
current responsibilities, she served also as Vice President, Full
Development, where she was responsible for the management oversight
of development leaders of the late stage pipeline.

Annalisa Jenkins is a British citizen.

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck KGaA,
Darmstadt, Germany, a global pharmaceutical and chemical company.
Headquartered in Geneva, Switzerland, Merck Serono discovers,
develops, manufactures and markets prescription medicines of both
chemical and biological origin in specialist indications. In the
United States
and Canada, EMD Serono operates as a separately
incorporated affiliate of Merck Serono.

Merck Serono has leading brands serving patients with cancer
(Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon
beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and
metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®,
sapropterin dihydrochloride), (Egrifta™, tesamorelin), as well as
cardiometabolic diseases (Glucophage®, metformin), (Concor®,
bisoprolol), (Euthyrox®, levothyroxine). Not all products are
available in all markets.

With an annual R&D expenditure of over € 1bn, Merck Serono
is committed to growing its business in specialist-focused
therapeutic areas including neurodegenerative diseases, oncology,
fertility and endocrinology, as well as new areas potentially
arising out of research and development in rheumatology.

About Merck

Merck is a global pharmaceutical and chemical company with total
revenues of € 9.3 billion in 2010, a history that began in 1668,
and a future shaped by more than 40,000 employees in 67 countries.
Its success is characterized by innovations from entrepreneurial
employees. Merck’s operating activities come under the umbrella of
Merck KGaA, in which the Merck family holds an approximately 70%
interest and free shareholders own the remaining approximately 30%.
In 1917 the U.S. subsidiary Merck & Co. was expropriated and
has been an independent company ever since.

For more information, please visit or

Merck Serono S.A. - Geneva, 9 Chemin des Mines 1202 Genève, Suisse, Media relations, Tel: +41-22-414-36-00

will not be displayed